Letter from Rigel Points to New Safety Signal of Pralsetinib in RET+ NSCLC
Data from the AcceleRET-Lung trial show an imbalanced risk of severe and fatal infection with pralsetinib for patients with RET fusion-positive NSCLC.
Related Articles
Plenary lecturer: Human Breast Cell Atlas charts pathway from healthy tissue to cancer – SABCS Meeting News
Walid Khaled, PhD, on Friday discussed work to draw a map of how the breast changes during tumorigenesis and progression.
Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification
China’s NMPA has granted priority review to the NDA for savolitinib plus osimertinib in pretreated EGFR-mutated advanced NSCLC with MET amplification.
European Commission Approves Lazertinib Plus Amivantamab in First-Line EGFR-Mutated NSCLC
The European Commission has approved a type II variation extended indication for lazertinib plus amivantamab in frontline EGFR-mutated NSCLC.
Fred Hutch receives funding to advance Indigenous cancer health equity
Fred Hutch Cancer Center’s Lonnie A. Nelson, PhD; Jason Mendoza, MD, MPH; and Myra Parker, JD, MPH, PhD, were awarded a U19 cooperative agreement from…
Highlights of ASH in North America
Join the world’s leading hematology experts at Highlights of ASH in North America, a two-day program offered in multiple locations that highlights the most influential…
Incretin mimetics in reducing breast cancer risk
Neil Iyengar, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the potential of incretin mimetics to reduce breast cancer risk, particularly in…
PM8002/BNT327 Combo Improves Efficacy and Safety in Metastatic TNBC
Data from a phase 1b/2 study show a 78.6% ORR in patients with metastatic triple-negative breast cancer treated with PM8002/BNT327 plus nab-paclitaxel.
Patients with heart disease may be at increased risk for advanced breast cancer
Cardiovascular disease (CVD) and cancer are the two leading causes of death in the U.S. According to researchers from The University of Texas MD Anderson…
